CoChat
Sign Up
Cited by 7

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Validation of the Nanjing Criteria for Diagnosing Pyrrolizidine Alkaloids-induced Hepatic Sinusoidal Obstruction Syndrome

Zhang, Wei, Liu, Lu, Zhang, Ming, Zhang, Feng, Peng, Chunyan, Zhang, Bin, Chen, Jun, Li, Lin, He, Jian, Xiao, Jiangqiang, Feng, Yanhong, Wang, Xunjiang, Xiong, Aizhen, Yang, Li, Zou, Xiaoping, Yu, Yuecheng, Zhuge, Yuzheng·2021·Journal of Clinical and Translational Hepatology
DOI 10.14218/jcth.2020.00124PMC PMC8237138
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.14218/jcth.2020.00124

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Show all 2 references

Research works printed but not linked: 27

  1. Fan, 2014, Sinusoidal obstruction syndrome (hepatic veno-occlusive disease), J Clin Exp Hepatol, 4, 332, 10.1016/j.jceh.2014.10.002 · DOI
  2. Zhuge, 2018, Clinical characteristics and treatment of pyrrolizidine alkaloid-related hepatic vein occlusive disease, Liver Int, 38, 1867, 10.1111/liv.13684 · DOI
  3. Lin, 2011, Hepatic sinusoidal obstruction syndrome associated with consumption of Gynura segetum, J Hepatol, 54, 666, 10.1016/j.jhep.2010.07.031 · DOI · Paper page
  4. Wang, 2014, Tusanqi and hepatic sinusoidal obstruction syndrome, J Dig Dis, 15, 105, 10.1111/1751-2980.12112 · DOI
  5. Xu, 2009, Raise the recognition of hepatic veno-occlusive disease induced by chrysanthemum-like groundsel, Chin J Gastroen, 14, 577
  6. Zhuge, 2019, Expert consensus on the clinical management of pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome, J Gastroenterol Hepatol, 34, 634, 10.1111/jgh.14612 · DOI · Paper page
  7. Dalle, 2016, Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: risk factors and stratification, prophylaxis, and treatment, Biol Blood Marrow Transplant, 22, 400, 10.1016/j.bbmt.2015.09.024 · DOI
  8. Chen, 2010, Hepatic veno-occlusive disease associated with toxicity of pyrrolizidine alkaloids in herbal preparations, Neth J Med, 68, 252
  9. Zhu, 2012, Clinical analysis of 50 cases of hepatic veno-occlusive disease, Chin J Dig, 32, 620
  10. Gu, 2010, Clinical features of hepatic veno-occlusive disease caused by Gynura segetum (Lour.) Merr, Chin J Dig, 30, 771
  11. Dignan, 2013, BCSH/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation, Br J Haematol, 163, 444, 10.1111/bjh.12558 · DOI
  12. 2016, EASL Clinical Practice Guidelines: Vascular diseases of the liver, J Hepatol, 64, 179, 10.1016/j.jhep.2015.07.040 · DOI
  13. 2018, EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis, J Hepatol, 69, 406, 10.1016/j.jhep.2018.03.024 · DOI
  14. 2018, EASL Clinical Practice Guidelines: Management of alcohol-related liver disease, J Hepatol, 69, 154, 10.1016/j.jhep.2018.03.018 · DOI
  15. 2017, EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection, J Hepatol, 67, 370, 10.1016/j.jhep.2017.03.021 · DOI
  16. 2017, EASL Recommendations on Treatment of Hepatitis C 2016, J Hepatol, 66, 153, 10.1016/j.jhep.2016.09.001 · DOI
  17. 2017, EASL Clinical Practical Guidelines on the management of acute (fulminant) liver failure, J Hepatol, 66, 1047, 10.1016/j.jhep.2016.12.003 · DOI · Paper page
  18. Chalasani, 2014, ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury, Am J Gastroenterol, 109, 950, 10.1038/ajg.2014.131 · DOI · Paper page
  19. McDonald, 1984, Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors, Hepatology, 4, 116, 10.1002/hep.1840040121 · DOI
  20. McDonald, 1993, Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients, Ann Intern Med, 118, 255, 10.7326/0003-4819-118-4-199302150-00003 · DOI
  21. Jones, 1987, Venoocclusive disease of the liver following bone marrow transplantation, Transplantation, 44, 778, 10.1097/00007890-198712000-00011 · DOI
  22. Gao, 2015, Blood pyrrole-protein adducts as a diagnostic and prognostic index in pyrrolizidine alkaloid-hepatic sinusoidal obstruction syndrome, Drug Des Devel Ther, 9, 4861, 10.2147/DDDT.S87858 · DOI · Paper page
  23. Kan, 2016, Diagnostic performance of Contrast-enhanced CT in Pyrrolizidine Alkaloids-induced Hepatic Sinusoidal Obstructive Syndrome, Sci Rep, 6, 37998, 10.1038/srep37998 · DOI
  24. Gao, 2012, Definitive diagnosis of hepatic sinusoidal obstruction syndrome induced by pyrrolizidine alkaloids, J Dig Dis, 13, 33, 10.1111/j.1751-2980.2011.00552.x · DOI · Paper page
  25. Ma, 2018, Determination and regulation of hepatotoxic pyrrolizidine alkaloids in food: A critical review of recent research, Food Chem Toxicol, 119, 50, 10.1016/j.fct.2018.05.037 · DOI
  26. Xia, 2016, Pyrrolizidine alkaloid-protein adducts: Potential non-invasive biomarkers of pyrrolizidine alkaloid-induced liver toxicity and exposure, Chem Res Toxicol, 29, 1282, 10.1021/acs.chemrestox.6b00120 · DOI
  27. Fu, 2002, Pyrrolizidine Alkaloids-Tumorigenic Components in Chinese Herbal Medicines and Dietary Supplements, J Food Drug Anal, 10, 198

Cited by

Sorted by citations

See all 7

Metadata

Authors
Zhang, W., Liu, L., Zhang, M., Zhang, F., Peng, C., Zhang, B., Chen, J., Li, L., He, J., Xiao, J., Feng, Y., Wang, X., Xiong, A., Yang, L., Zou, X., Yu, Y., & Zhuge, Y.
Venue
Journal of Clinical and Translational Hepatology
Publisher
Xia & He Publishing
Published
2021-03-31
Volume
000
Issue
000
Pages
000-000
ISSN
  • 2225-0719
  • 2310-8819
DOI
10.14218/jcth.2020.00124
PMC
PMC8237138
Cited by
7
References
2
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review